Inovio Pharmaceuticals appoints Wendy Yarno to its Board of Directors

– USA, PA – Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that Wendy Yarno has been elected to the company’s Board of Directors. Wendy Yarno has over 25 years of experience in the pharmaceutical industry highlighted by her tenure at Merck & Co. where she served as chief marketing officer.

At Merck, Ms. Yarno led a global organization charged with all aspects of supporting pre- and post-launch commercialization of pharmaceuticals in more than 20 therapeutic areas. She also previously served as General Manager, Cardiovascular/Metabolic U.S. Business Unit, where she had P&L responsibility for Merck’s largest therapeutic area, and as Senior Vice President, Human Resources. Earlier in her career she was vice president of the women’s health care franchise for Johnson & Johnson’s Ortho-McNeil Pharmaceutical subsidiary.

Dr. J. Joseph Kim, President and CEO, said, “Wendy Yarno joins Inovio at a critical point in our development as we pivot to a late-stage clinical company with significant big pharma partnerships. Her expertise and counsel will be invaluable to Inovio as we move toward product commercialization and additional industry alliances.”

Wendy Yarno has served on the boards of successful biopharmaceutical and medical technology companies, including Medivation Inc., St. Jude Medical Inc., and Durata Therapeutics Inc. She currently serves on the boards of Alder Biopharmaceuticals, Aratana Therapeutics Inc. and MyoKardia, Inc. Ms. Yarno holds a master’s degree in business administration from Temple University’s Fox School of Business and a bachelor’s degree in business administration from Portland State University.

About Inovio Pharmaceuticals, Inc.

Inovio is taking immunotherapy to the next level in the fight against cancer and infectious diseases. We are the only immunotherapy company that has reported generating T cells in vivo in high quantity that are fully functional and whose killing capacity correlates with relevant clinical outcomes with a favorable safety profile. With an expanding portfolio of immune therapies, the company is advancing a growing preclinical and clinical stage product pipeline. Partners and collaborators include MedImmune, Regeneron, Genentech, The Wistar Institute, University of Pennsylvania, DARPA, GeneOne Life Science, Plumbline Life Sciences, ApolloBio Corporation, Drexel University, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, and Laval University.

For more information :

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Talent4Boards Team

here the original post =>